Chair of the Board of Directors, Caraway Therapeutics and Forendo Pharma
United States of America
Cristina Csimma is a biopharmaceutical leader with decades of experience in biotechnology, large
pharma and venture capital.
Dr. Csimma is the Chair of the Board of Directors of Caraway Therapeutics and Forendo Pharma, and a
Board Director of Seneca Biopharma, Idera Pharmaceuticals, and the T1D Exchange. She is a member of
the Muscular Dystrophy Association Venture Philanthropy Scientific Advisory Committee, the Harvard
MRCT Center External Advisory Board, and the NIH NINDS NeuroNEXT External Oversight Board.
Previously, Dr. Csimma was the Executive Chair of the Board of Directors of Exonics Therapeutics, and a
Board Director of Juniper Pharma, Vtesse, and Cydan, where she was also the founding President and
CEO. Earlier in her career, Dr. Csimma was a principal with Clarus Ventures LLC (now Blackstone), VP of Drug Development at Virdante Pharmaceuticals, Inc., and held multiple roles in Clinical Development
and Translational Research at Wyeth (now Pfizer) and Genetics Institute, and Dana-Farber Cancer
Dr. Csimma holds a Doctor of Pharmacy and a Bachelor of Science from Massachusetts College of Pharmacy, as well as a Master of Health Professions from Northeastern University.